[go: up one dir, main page]

IL155178A0 - Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation - Google Patents

Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation

Info

Publication number
IL155178A0
IL155178A0 IL15517801A IL15517801A IL155178A0 IL 155178 A0 IL155178 A0 IL 155178A0 IL 15517801 A IL15517801 A IL 15517801A IL 15517801 A IL15517801 A IL 15517801A IL 155178 A0 IL155178 A0 IL 155178A0
Authority
IL
Israel
Prior art keywords
mutants
preparation
multiple sclerosis
chemokine
new
Prior art date
Application number
IL15517801A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL155178A0 publication Critical patent/IL155178A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15517801A 2000-10-04 2001-10-03 Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation IL155178A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
IL155178A0 true IL155178A0 (en) 2003-11-23

Family

ID=8170011

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15517801A IL155178A0 (en) 2000-10-04 2001-10-03 Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation
IL155178A IL155178A (en) 2000-10-04 2003-04-01 Use of Kamokin mutants to prepare a drug for the treatment of multiple sclerosis, such new mutants and their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155178A IL155178A (en) 2000-10-04 2003-04-01 Use of Kamokin mutants to prepare a drug for the treatment of multiple sclerosis, such new mutants and their preparation

Country Status (30)

Country Link
US (1) US7402303B2 (et)
EP (1) EP1326628B1 (et)
JP (1) JP3908165B2 (et)
KR (1) KR100837898B1 (et)
CN (1) CN1285381C (et)
AR (1) AR030854A1 (et)
AT (1) ATE265222T1 (et)
AU (2) AU1591902A (et)
BG (1) BG66137B1 (et)
BR (1) BR0114407A (et)
CA (1) CA2423616C (et)
CZ (1) CZ303409B6 (et)
DE (1) DE60103078T2 (et)
DK (1) DK1326628T3 (et)
EA (1) EA006137B1 (et)
EE (1) EE05174B1 (et)
ES (1) ES2217199T3 (et)
HR (1) HRP20030215B1 (et)
HU (1) HUP0302194A3 (et)
IL (2) IL155178A0 (et)
MX (1) MXPA03003008A (et)
NO (1) NO330278B1 (et)
PL (1) PL204231B1 (et)
PT (1) PT1326628E (et)
RS (1) RS50738B (et)
SI (1) SI1326628T1 (et)
SK (1) SK287523B6 (et)
UA (1) UA77950C2 (et)
WO (1) WO2002028419A2 (et)
ZA (1) ZA200302315B (et)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320743T3 (es) 2001-12-17 2009-05-28 Laboratoires Serono Sa Mutantes de quimiocina que actuan como antagonistas de quimiocinas.
WO2003084562A1 (en) * 2002-04-04 2003-10-16 Applied Research Systems Ars Holding N.V. Chemokines mutants having improved oral bioavailability
CA2507008A1 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
ATE415420T1 (de) * 2003-10-22 2008-12-15 Serono Lab Cxcl8-antagonisten
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
PT1439191E (pt) * 2004-01-19 2006-06-30 Ares Trading Sa Processo para a purificacao de proteinas expressas de forma bacteriana
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
US8012474B2 (en) 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
EP2539354B1 (en) * 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
CN112469430B (zh) 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
US20250186520A1 (en) * 2020-10-26 2025-06-12 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832197T2 (de) * 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor Rantes-mutanten und therapeutische anwendungen davon
CA2361256A1 (en) * 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
MXPA03003008A (es) 2003-07-14
CN1477969A (zh) 2004-02-25
IL155178A (en) 2009-07-20
HUP0302194A2 (hu) 2003-10-28
EA200300439A1 (ru) 2003-08-28
DE60103078D1 (de) 2004-06-03
ZA200302315B (en) 2004-03-25
EP1326628B1 (en) 2004-04-28
JP2004510426A (ja) 2004-04-08
NO20031525D0 (no) 2003-04-03
EA006137B1 (ru) 2005-10-27
ES2217199T3 (es) 2004-11-01
AU1591902A (en) 2002-04-15
US20040101509A1 (en) 2004-05-27
SK287523B6 (sk) 2011-01-04
SK4062003A3 (en) 2003-08-05
CA2423616A1 (en) 2002-04-11
EP1326628A2 (en) 2003-07-16
HRP20030215B1 (en) 2011-09-30
NO20031525L (no) 2003-04-03
EE05174B1 (et) 2009-06-15
DE60103078T2 (de) 2005-04-07
SI1326628T1 (en) 2004-10-31
US7402303B2 (en) 2008-07-22
DK1326628T3 (da) 2004-08-09
ATE265222T1 (de) 2004-05-15
BG66137B1 (bg) 2011-07-29
YU25703A (sh) 2006-05-25
BG107685A (bg) 2003-11-28
HUP0302194A3 (en) 2005-12-28
WO2002028419A3 (en) 2002-06-13
JP3908165B2 (ja) 2007-04-25
CN1285381C (zh) 2006-11-22
PL362350A1 (en) 2004-10-18
PT1326628E (pt) 2004-09-30
UA77950C2 (en) 2007-02-15
AU2002215919B2 (en) 2005-11-24
WO2002028419A2 (en) 2002-04-11
CZ2003947A3 (cs) 2003-11-12
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
PL204231B1 (pl) 2009-12-31
NO330278B1 (no) 2011-03-21
BR0114407A (pt) 2003-07-29
EE200300139A (et) 2003-06-16
HRP20030215A2 (en) 2005-02-28
HK1062811A1 (en) 2004-11-26
CA2423616C (en) 2010-03-16
AR030854A1 (es) 2003-09-03
RS50738B (sr) 2010-08-31
CZ303409B6 (cs) 2012-09-05

Similar Documents

Publication Publication Date Title
AP2000002015A0 (en) Pyrrolo¬2,3d¾pyrimidine compositions and their use
AU2001253456A1 (en) Antithrombogenic membrane mimetic compositions and methods
HUP0104496A3 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
EP1414841A4 (en) Oligonucleotide-containing pharmaceutical compositions and their use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
IL155178A0 (en) Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation
ZA978089B (en) 3,4-diaryloxazolone derivatives, their methods of preparation, and their use in therapeutics.
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
MXPA02000779A (es) Factor de activacion de la citocina altamente purificada y metodos de uso.
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
HUP0303936A3 (en) Novel composition and use
IL147414A0 (en) Ifnar2 mutants, their production and use
HUP0102988A3 (en) Peroxides, their preparation process and use
AU2001289281A1 (en) Novel polypeptide--- a human hepatic nuclear factor 12 and polynucleotide encoding it
AU5104101A (en) Composition and use
AU2001269106A1 (en) Novel alpha expressed in heart and testis
AU7660601A (en) Pseudo-metalloproteins, their preparation and use
HUP0104267A3 (en) 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiane and 1,4-diaryl-2-fluoro-2-butene compounds
GB0013238D0 (en) Novel composition and use
GB0106809D0 (en) Organomagnesium fluorides and preparation of
HK1057490A (en) Osteopontin-coated surfaces and methods of use
GB9826894D0 (en) Chemokine and uses thereof
AU5025801A (en) Novel polypeptide---a human hexose kinase 13 and polynucleotide encoding it
SI1379639T1 (sl) Misja glukoronil C5-epimeraza, DNA, ki kodira le-to, in njena uporaba